List of the patients, clinical, and treatment data

Patient	Sex	Aetiology of facial palsy	Injection sessions (n)	Dose of injected toxin in different injection sessions (range (mu))	Range of clinical effect on synkinesia (S) and hyperlacrimation (H)	Mean difference (%)
1	67	F	A: Yes	Idiopathic	?	2	60–120	S: 4	—
			B: No
			C: No
2	85	F	A: Yes	Idiopathic	2	8	40–120	S: 2–4	+57
			B: No
			C: No
3	58	F	A: Yes	Idiopathic	30	5	60–120	S: 4	—
			B: Yes					H: 1–2
			C: No
4	74	F	A: Yes	Idiopathic	1	1	70	S: 3	—
			B: Yes					H: 2
			C: No
5	80	F	A: Yes	Idiopathic	1	5	60–100	S: 2–4	+47
			B: No
			C: No
6	70	M	A: Yes	Zoster oticus		5	70–80	S: 2–4	+45
			B: Yes					H: 2
			C: No
7	68	M	A: Yes	Resection of acusticus neurinoma		7	1	80	S: 3	+67
			B: Yes						H: 1
			C: No
8	31	F	A: Yes	Idiopathic	5	2	80–100	S: 4	+26
			B: Yes					H: 2
			C: No
9	34	F	A: Yes	Idiopathic	4	1	60	S: 4	—
			B: Yes					H: 2
			C: No
10	26	F	A: Yes	Idiopathic	4	2	60	S: 4	+40
			Hypolacrimation					H: No clinical effect on hypolacrimation
			C: No					H: No clinical effect on hypolacrimation

Videographic assessment of the width of the affected lid was performed before and 2–4 weeks after the BTX A injection in patients 2, 5, 6, 7, 8, and 10.
A=synkinesias; B=hyperlacrimation; C=gustatory sweating.
Mean difference=mean difference between relative width of affected lid before and 2–4 weeks after treatment vunaffected side.